{
    "clinical_study": {
        "@rank": "142866", 
        "arm_group": [
            {
                "arm_group_label": "medically stable active injecting drug users", 
                "description": "Medically stable active injecting drug users- injection of heroin with or without other agents at least 3 times a week (N=48);"
            }, 
            {
                "arm_group_label": "non-injecting controls", 
                "description": "non-injecting controls- no lifetime use of injection drugs and no illicit non-injection opiate or cocaine for at least 3 years"
            }, 
            {
                "arm_group_label": "Former injectors of heroin with or without other agents", 
                "description": "Former injectors of heroin with or without other agents will be recruited and followed longitudinally but if necessary cross-sectionally after approximately 1 month (N=48) and 3 months (N=48) from the time of last injection"
            }
        ], 
        "biospec_descr": {
            "textblock": "Sigmoidoscopy with biopsy"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The goal of this study is to learn how injection drug use may affect the immune system."
        }, 
        "brief_title": "Correlates and Consequences of Increased Immune Activation in Injection Drug Users", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "The goal of this study is to learn how injection drug use may affect the immune system. One\n      way to measure this is by looking at the blood and the gut, or gastrointestinal tract at the\n      same time. It is thought that activating the immune system by injection drug use may\n      increase destruction of immune cells in the gut. To test this theory, the investigators are\n      enrolling HIV-negative injection drug users, HIV-negative people who do not use drugs and\n      HIV-negative former injection drug users."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to give informed consent\n\n          -  Between the ages of 18 and 55\n\n          -  Absence of medical conditions that would preclude flexible sigmoidoscopy\n\n          -  Absence of active opportunistic infection requiring active therapy including\n             antibiotics or antineoplastics (note this does not include prophylactic antibiotic\n             therapy)\n\n        Exclusion Criteria:\n\n          -  History of bleeding disorder\n\n          -  Platelet count below 70,000\n\n          -  INR>1.5 or PTT>2X control\n\n          -  Active use of anticoagulants or aspirin therapy that cannot be interrupted\n\n          -  Comorbid diagnosis of inflammatory bowel disease\n\n          -  Pregnancy, incarceration, mentally disabled individuals\n\n          -  HIV-1 infection\n\n          -  Currently on Hepatitis C treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Group 1: HIV-uninfected, active IDU defined as a minimum of 3 injections of heroin per\n        week (N=48)\n\n        Group 2: Non-injecting controls defined as no lifetime use of injection drugs and no\n        illicit non-injection opiate or cocaine for at least 3 years (N=48)\n\n        Group 3: Former injectors of heroin with or without other agents will be recruited and\n        followed longitudinally but if necessary cross-sectionally after approximately 1 month\n        (N=48) and 3 months (N=48) from the time of last injection.\n\n        All groups will be matched for age, sex, and race/ethnicity. Groups 1 and 3 will be\n        matched for Hepatitis C status and HCV RNA levels. Group 1 subjects will be studied twice;\n        at baseline and after 1-2 months to assess stability of findings. Group 2 will be studied\n        one time, and Group 3 will be studied at 1 month and 3 months after ceasing injection\n        behavior."
            }
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831284", 
            "org_study_id": "MMA-0774"
        }, 
        "intervention": {
            "arm_group_label": [
                "medically stable active injecting drug users", 
                "non-injecting controls", 
                "Former injectors of heroin with or without other agents"
            ], 
            "description": "Sigmoidoscopy with biopsy", 
            "intervention_name": "Sigmoidoscopy with biopsy", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 14, 2013", 
        "location": {
            "contact": {
                "last_name": "Recruitment Office", 
                "phone": "212-782-2737"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "The Rockfeller University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Correlates and Consequences of Increased Immune Activation in Injection Drug Users", 
        "overall_official": {
            "affiliation": "ADARC", 
            "last_name": "Martin Markowitz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Detailed assessments of blood and GI tissue including measurements of HCV viremia in 1) active HIV-1-uninfected IDUs (N=48) 2) a cohort of individuals entering or in drug treatment programs who have stopped injecting for approximately 1 and 3 months (N=48), the majority of whom we anticipate will be infected with HCV; and 3) non-injecting controls (N=48). In addition to obtaining blood and tissue, we will collect behavioral data including injection and other drug use and sexual behaviors.", 
            "measure": "Examine the behavioral and immunological correlates of increased immune activation in active and former injection drug users (IDUs) in blood and tissue.", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831284"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "This study will isolate specific cell populations from the peripheral blood as well as the GALT that mediate innate and adaptive immune responses. We will perform transcriptional profiling with the goal of identifying gene expression patterns of a-priori defined biological pathways and functional categories that associate with phenotypes of interest. Finally to complement and clarify the results of our in vivo studies, we will examine the in vitro effects of adding morphine and methadone and withdrawing opiates on T cell subsets of interest using a systems biology approach.", 
            "measure": "Determine the mechanisms of increased immune activation associated with active IDU using a systems biology approach.", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Rockefeller University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rockefeller University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}